Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized...

Area of Science:

• Oncology
• Clinical Trials
• Molecular Oncology

Background:

• Colon cancer is a significant global health concern.
• PIK3CA mutations are found in a subset of colon cancer patients.
• The role of adjuvant therapy in PIK3CA-mutant colon cancer requires further investigation.

Purpose of the Study:

• To assess the efficacy of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer.
• To evaluate the impact of aspirin on disease-free survival (DFS) and time to recurrence (TTR).

Main Methods:

• Phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, multinational trial.
• 112 patients with resected stage II/III PIK3CA-mutant colon cancer randomized (2:1) to aspirin (100mg daily for 3 years) or placebo.
• Primary endpoint: DFS. Secondary endpoints: TTR, overall survival, adverse events (AEs).

Main Results:

• A trend favoring aspirin for DFS (HR 0.57, p=0.11) and TTR (HR 0.49, p=0.089) was observed.
• Five-year DFS rates were 86.5% with aspirin vs. 72.9% with placebo.
• No serious aspirin-related adverse events were reported.

Conclusions:

• The SAKK 41/13 trial provides the first randomized evidence suggesting a protective effect of adjuvant aspirin in PIK3CA-mutant colon cancer.
• Clinically relevant improvements in DFS and TTR were noted, warranting consideration for adjuvant aspirin in this patient population.
• Premature study closure limited statistical significance, but results support individual consideration of aspirin for resected PIK3CA-mutant colon cancer.